FOLD - Amicus Therapeutics Inc

FOLD - Amicus Therapeutics Inc

https://amicusrx.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - Amicus Therapeutics ( NASDAQ:FOLD )

Benzinga • 2 weeks, 3 days ago • score: 0.36

PRINCETON, N.J., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics FOLD today announced that management will participate in upcoming presentations at the following investor conferences in September. Cantor Global Healthcare Conference 2025 in New York, NY, on Wednesday, September 3, ...

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

GlobeNewswire • 2 weeks, 3 days ago • score: 0.47

PRINCETON, N.J., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics ( Nasdaq: FOLD ) today announced that management will participate in upcoming presentations at the following investor conferences in September.

Earnings Estimates Moving Higher for Amicus Therapeutics ( FOLD ) : Time to Buy?

Zacks Commentary • 1 month, 1 week ago • score: 0.63

Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales

Zacks Commentary • 1 month, 1 week ago • score: 0.06

Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.

Amicus Therapeutics ( FOLD ) Misses Q2 Earnings Estimates

Zacks Commentary • 1 month, 2 weeks ago • score: 0.12

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -50.00% and +4.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.

52W High

$12.65

52W Low

$5.51

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.53

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

285.71

EV/EBITDA (<8 favorable)

77.37

EV/Revenue (<3 favorable)

4.48

P/S (TTM) (<3 favorable)

4.11

P/B (<3 favorable)

11.48

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.72%

Institutions (25–75% balanced)

104.75%

Shares Outstanding

308,239,000

Float

288,207,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

571,160,000

Gross Profit (TTM)

516,130,000

EPS (TTM)

-0.12

Profit Margin (>10% good)

-0.07%

Operating Margin (TTM) (higher better)

-0.05%

ROE (TTM) (>15% strong)

-0.23%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.22

Momentum

Bearish momentum

Value

0.3565

Previous

0.3701

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025